Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

This study (FAROUT Trial) tests an experimental immunotherapy vaccine called FRαDCs — made from a patient's own immune cells — for women with advanced stage III or IV ovarian, fallopian tube, or primary peritoneal cancer. The vaccine is given after standard surgery and chemotherapy to try to prevent the cancer from coming back. **You may be eligible if...** - You are 18 or older with confirmed stage III or IV ovarian, fallopian tube, or primary peritoneal cancer - Your cancer is high-grade serous, endometrioid, or clear cell type - You have completed surgery (including hysterectomy and removal of both ovaries) and one course of platinum-based chemotherapy (5–9 cycles) within the past 4–12 weeks - You do not carry BRCA1 or BRCA2 gene mutations - Your blood counts and immune cell levels meet required thresholds **You may NOT be eligible if...** - You carry a BRCA1 or BRCA2 mutation - You have received more than one course of chemotherapy or treatment for a cancer recurrence - You have a poor performance status or serious infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.